Privileged Scaffolds for Potent and Specific Inhibitors of Mono-ADP-Ribosylating PARPs

The identification of new targets to address unmet medical needs, better in a personalized way, is an urgent necessity. The introduction of PARP1 inhibitors into therapy, almost ten years ago, has represented a step forward this need being an innovate cancer treatment through a precision medicine ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Nizi, Maria Giulia, Sarnari, Chiara, Tabarrini, Oriana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10420676/
https://www.ncbi.nlm.nih.gov/pubmed/37570820
http://dx.doi.org/10.3390/molecules28155849

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10420676/
https://www.ncbi.nlm.nih.gov/pubmed/37570820
http://dx.doi.org/10.3390/molecules28155849

Ejemplares similares